Drug Profile
ZW 38
Alternative Names: ZW-38Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action CD antigen modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leukaemia; Lymphoma
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Leukaemia in Canada (Parenteral) (Zymeworks pipeline, September 2023)
- 18 Sep 2023 Discontinued - Preclinical for Lymphoma in Canada (Parenteral) (Zymeworks pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Leukaemia in Canada (Parenteral)